Becton, Dickinson and CompanyBDX, popularly known as BD, recently announced that the FDA has granted 510(k) clearance for its ...

"BD secures FDA 510 (k) clearance for EnCor EnCompass system" was originally created and published by Hospital Management, a ...

BD (NYSE: BDX) announced today that the FDA granted 510(k) clearance for its EnCore EnCompass breast biopsy and tissue ...

Becton, Dickinson and Co. will invest more than $110M to expand a Nebraska syringe facility, add 120 jobs and support ...

Waters Corp. and BD announced a definitive agreement July 14 to combine BD’s Biosciences & Diagnostic Solutions businesses with the Milford, Mass.-based company. The deal is structured as a ...

Earlier this year, BD revealed its intent to split from its lifesciences and diagnostic solutions business to become a pure-play medical device company. On the surface, medtech analysts have largely ...

BD, a leading global medical technology company, and Frazier Healthcare Partners, a leading private equity firm focused exclusively on the healthcare sector, announced a definitive agreement for BD to ...

After racking up a string of acquisitions throughout 2022—including one of the medtech industry’s largest of the year in its $1.5 billion buyout of Parata Systems—BD has yet to make any major ...

Ever since COVID hit, supply chain executives have embraced supply chain risk management. Within this discipline, one of the toughest challenges is how to get visibility to problems arising across the ...

As the market for GLP-1 injections continues to grow, BD aims to ride that wave by providing drugmakers with its prefilled syringes. Biologic medications—including those blockbusters for diabetes and ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will host its virtual 2026 Annual Meeting of Shareholders (the "Annual Meeting") on ...